rss
J Neurol Neurosurg Psychiatry doi:10.1136/jnnp.2007.123323

Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson’s disease

  1. Fabian Klostermann (fabian.klostermann{at}charite.de)
  1. Charité - University Medicine Berlin, Department of Neurology, Germany
    1. Felicitas Ehlen
    1. Charité - University Medicine Berlin, Department of Neurology, Germany
      1. Jan Vesper
      1. University Clinic of Freiburg, Department of Stereotactic Neurosurgery, Germany
        1. Karsten Nubel
        1. Charité - University Medicine Berlin, Deparment of Audiology and Phoniatrics, Germany
          1. Manfred Gross
          1. Charité - University Medicine Berlin, Deparment of Audiology and Phoniatrics, Germany
            1. Frank Marzinzik
            1. Charité - University Medicine Berlin, Department of Neurology, Germany
              1. Gabriel Curio
              1. Charité - University Medicine Berlin, Department of Neurology, Germany
                1. Tanja Sappok
                1. Charité - University Medicine Berlin, Department of Neurology, Germany
                  • Published Online First 31 August 2007

                  Abstract

                  Background: Motor deficits in Parkinson’s disease (PD) are reduced by Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN), but the impact of this therapy on dysarthrophonic problems in PD remains controversial. We, therefore, aimed at disentangling the effects of STN DBS on the speech skills of long-term treated patients.

                  Methods: Under continued medication, speech and motor functions of 19 PD patients with bilateral STN DBS were studied when their therapeutic stimulation was active (STIM-ON) versus switched off (STIM-OFF). Per condition, perceptual speech ratings were given by (i) the patients themselves, (ii) the treating physician and (iii) professional speech therapists. Further, single speech parameters were measured with a battery of technical exams in both STIM-ON and STIM-OFF.

                  Results: STN DBS significantly worsened speech performance according to all perceptual rating methods applied. Contrarily, technical measures showed DBS-induced improvements of single speech dimensions affected by the PD-specific motor disorder. These changes occurred independently of the reduction of motor impairment, consistently effectuated by STN DBS.

                  Conclusion: In parallel to the beneficial effects of STN DBS on the motor symptoms of PD, it reduces designated disease-inherent dysarthrophonic symptoms, such as glottic tremor. However, these actions on speech are predominantly outweighed by general dysarthrogenic effects of STN DBS, probably based on a decline of complex, e.g., prosodic functions. Thus, on condition of the reduced antiparkinsonian medication under DBS STN, stimulation-induced speech impairment should be considered a likely problem in the course of the treatment.

                  Register for free content

                  The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

                  Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

                  BMJ Careers - Latest neurology and neurosurgery jobs